What is Biogen's qalsody eu — research and development:?

Biogen (BIIB) reported qalsody eu — research and development: of $5.00M in Q4 2024.

What does qalsody eu — research and development: mean?

The total research and development expenses dedicated to the QALSODY product line within the European market.

Discontinued — last reported Q4 '24

Products & Services · Research and development:

QALSODY EU — Research and development:

Biogen QALSODY EU — Research and development: remained flat by 0.0% to $5.00M in Q4 2024 compared to the prior quarter.

Analysis

StatementSegment

CategoryEfficiency

SignalContext dependent

VolatilityModerate

First reportedQ1 2024

Last reportedQ4 2024

Rolls up toR&D

How to read this metric

An increase typically signals intensified investment in clinical trials or regulatory compliance for the product, while a decrease may indicate the completion of major studies or a shift in strategic focus for the European market.

Detailed definition

This metric represents the direct costs incurred for research, clinical trials, and regulatory development activities sp...

Peer comparison

Comparable to product-specific R&D allocations at other biopharmaceutical firms, which are often reported as part of segment-level operating expenses or specific therapeutic area investments.

Metric ID: biib_segment_qalsody_eu_research_and_development

Historical Data

1 years

	FY'24
Value	$20.00M

Similar Metrics at Other Companies

IQVIAIQV View metric

AmgenAMGN View metric

IQVIAIQV View metric

Frequently Asked Questions

What is Biogen's qalsody eu — research and development:?: Biogen (BIIB) reported qalsody eu — research and development: of $5.00M in Q4 2024.
What does qalsody eu — research and development: mean?: The total research and development expenses dedicated to the QALSODY product line within the European market.